Soybean production in Iowa USA is among the most productive for rainfed regions in the world. Despite generally having excellent soils, growing season temperatures and rainfall, soybean yields are decreased by weed interference and inadequate available soil water at key stages of crop development. A field study was conducted at two locations in Iowa in 2012 to determine if seed-applied fungicide or biofield treatments influenced weed community, soil volumetric water concentration and soybean yield and quality. Application of biofield treatment resulted in lower density of tall waterhemp density, greater soybean stand density at R8 stage and greater seed pod–1 compared to the absence of seed fungicide and biofield. Soil volumetric water content varied by seed fungicide x biofield x date interaction but differences were not consistent among treatment combinations. Overall, seed fungicide and biofield treatments had similar effects on soybean productivity, however additional research is necessary to determine if biofield treatment is a suitable replacement for seed fungicide application.
The aim was to study the effect of the Consciousness Energy Treated test formulation on vital organ functions viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media were divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Alan Joseph Balmer, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was found as safe and non-toxic in six different cells. The Biofield Energy Treated medium (BT-Med) + Biofield Energy Treated Test Item (BT-TI) group showed 181% and 82.2% restoration of cell viability at 1 and 10 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. The UT-Med + BT-TI group showed 126.8% and 86.3% restoration of cell viability at 10 and 25 µg/mL, respectively with respect to the untreated group in human hepatoma cells (HepG2). Furthermore, 101.2% (at 10 µg/mL), 103.6% (at 10 µg/mL) and 135% (at 25 µg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 90%, 87.3% and 86.9% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 137% in the BT-Med + UT-TI group in human endometrial adenocarcinoma cells (Ishikawa) at 1 µg/mL compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 52.1%, 65.9% and 63.5% at 1 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 157% and 58.9% at 0.1 and 10 µg/mL, respectively in the BT-Med + BT-TI group compared to the untreated group in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 168% and 135.4% in the UT-Med + BT-TI group at 10 and 25 µg/mL, respectively; while, 137% at 10 µg/mL in the BT-Med + UT-TI group as compared to the untreated group. Serotonin level was significantly increased by 50.8% (at 63 µg/mL), 78.8% (at 63 µg/mL) and 52.7% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 265.5% (at 0.1 µg/mL) and 253.4% (at 1 µg/mL) in the UT-Med + BT-TI group; while 335.3% (at 0.1 µg/mL) in the BT-Med + BT-TI group compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the relevant bones, heart, liver, lungs and brain-related biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, Wilson disease, liver cancer, hemochromatosis, pneumonia, asthma, cystic fibrosis, emphysema, chronic bronchitis, osteoporosis, etc.
Multiple organ dysfunction syndrome or failure is one of the major concerns against healthcare services in order to maintain the normal function. The present study aimed to explore the impact of the Biofield Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain using standard activity parameters in specific cell-based assays. The test formulation and cells medium was divided into two parts, one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Ariadne Esmene Afaganis, Canada and was labeled as the Biofield Treated (BT) test formulation/media. The test formulation was tested for cell viability, and the data suggested that the test formulation was found safe and non-toxic against all the cell lines. Cytoprotective activity among the experimental groups showed a significant improved activity by 94.4% at 1 µg/mL in untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI) group in human cardiac fibroblasts cells (HCF) cells, while 84.4% at 10 µg/mL in BT-Med + BT-TI groups in human hepatoma cells (HepG2), and 124% increased cytoprotective action at 1 µg/mL in UT-Med + BT-TI group in adenocarcinomic human alveolar basal epithelial cells (A549) cells as compared with the untreated test group. ALP activity in MG-63 cells was significantly increased by 85.9% at 10 µg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 59.2% at 0.1 µg/mL in BT-Med + BT-TI groups as compared to the untreated group. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 53% and 40.5% at 1 and 10 µg/mL concentrations respectively, in UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 68.5%, 70.7%, and 16.8% at 0.1, 1, and 10 µg/mL respectively, and 86.5%, 62.5%, and 34.2% improved cellular protection at 0.1, 1, and 10 µg/mL respectively, in BT-Med + BT-TI group as compared to the untreated test group. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 33.5%, 63.2%, and 99.2% at 10 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by increased by 39.8% (at 10 µg/mL), 44% (at 25.5 µg/mL), and 59.7% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated group. Serotonin level was significantly increased by 59.2% (at 0.1 µg/mL), 190.3% (at 0.1 µg/mL), and 201% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 159.1% (at 50 µg/mL), 212.7% (at 1 µg/mL), and 278.3% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, the present data concluded that the overall multiple organ health using various standard biomarkers in specific cell lines were significantly improved with respect to health of bones, heart, liver, lungs, and brain after treatment with the Biofield Energy treated test formulation (The Trivedi Effect®). Thus, it can be used as a complementary and alternative therapy approach against many multiple organ disorders such as coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
The study objective was to investigate the effect of Consciousness Energy Healing-based vitamin D3 and DMEM medium on bone health. The test items (vitamin D3 and DMEM), were divided into two parts. One part of each sample was received the Biofield Energy Treatment by Debra Jane Schnitzer and those samples were denoted as the Biofield Energy Treated (BT) samples, while the other parts of each sample were referred as the untreated test items (UT). Parameters such as ALP, collagen, and bone mineralization were performed to evaluate the bone strength in human bone osteosarcoma cells (MG-63). The test samples were found as safe in the tested concentrations by MTT cell viability assay. ALP was significantly increased by 27.75%, 28.21%, and 60% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 50 µg/mL compared to the UT-DMEM + UT-Test item group. Moreover, the ALP level was significantly raised by 11.17% and 74.57% in the UT-DMEM + BT-Test item and BT-DMEM + BT-Test item groups, respectively at 100 µg/mL compared to the UT-DMEM + UT-Test item group. Collagen was significantly increased by 54.53% and 115.01% in the UT-DMEM + BT-Test item and BT-DMEM + UT-Test item groups, respectively at 0.1 µg/mL compared to the untreated group. Further, the collagen level was significantly increased by 131.87% (at 1 µg/mL) and 179.77% (at 10 µg/mL) in the UT-DMEM + BT-Test item group compared to the untreated group. Apart from this, the percent of bone mineralization was distinctly increased by 75.94%, 125.79%, and 117.38% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 10 µg/mL compared to the untreated group. Additionally, the percentage of bone mineralization was significantly increased by 46.08%, 173.22%, and 171.17% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 50 µg/mL compared to the untreated group. Altogether, the Biofield Energy Treated vitamin D3 was significantly improved the bone health parameters and it could be an alternative approach for nutraceutical supplement to combat vitamin D3 deficiency and able to fight against various bone-related disorders including rickets, low bone density, osteomalacia, bone and joint pain, bone fractures, osteoporosis, osteoma, osteogenesis imperfecta, Paget’s disease, deformed bones, chondrodystrophia fetalis, stress management and prevention, autoimmune and inflammatory diseases, and anti-aging by improving overall health.
The application of the herbomineral formulations in general skin health are increasing day-by-day due to the excellent outcomes without any adverse effects. This study was designed to evaluate the influence of The Trivedi Effect®-Consciousness Energy Healing Treatment on an herbomineral formulation and cell medium against various skin health parameters. The test formulation consists of minerals (zinc chloride, sodium selenate, and sodium molybdate) and L-ascorbic acid along with herbal extracts, Centella asiatica, and tetrahydrocurcumin (THC). The test formulation and DMEM media were divided into two equal parts, one was treated with a Biofield Treatment (BT) by Dezi Ann Koster and denoted as treated, while the other part was coded as the untreated (UT) groups. MTT assay results showed that test formulation was safe and nontoxic with more than 89% cell viability in the tested cell lines. BrdU assay showed an improved cell proliferation by 2.82% in the UT-DMEM + BT-Test formulation group compared with the untreated group. The level of collagen was significantly increased by 32.42%, 33.64%, and 29.13% at 2.5, 1.25 and 0.625 µg/mL, respectively in the UT-DMEM + BT-Test formulation, while34.17%, 26.73%, and 17.56% increased at 2.5, 1.25 and 0.625 µg/mL, respectively in BT-DMEM + BT-Test formulation group compared with the untreated group. Elastin level was increased by 408.6% at concentration of 0.625 µg/mL in UT-DMEM + BT-Test formulation group compared with untreated group. However, hyaluronic acid (HA) level was increased by 31.88%, 15.52%, and 58.29% at 2.5, 1.25, and 0.625 µg/mL, respectively in the BT-DMEM + BT-Test formulation group compared with untreated group. Besides, melanin synthesis was significantly inhibited by 16.09% and 18.93% in the UT-DMEM + BT-Test formulation and BT-DMEM + UT-Test formulation groups, respectively at 0.125 µg/mL compared with the untreated group. Anti-wrinkling activity in HFF-1 cells showed an improved cell viability by 5.49% and 11.26% at 1.25 and 0.625 µg/mL, respectively in BT-DMEM + BT-Test formulation group compared with the untreated group. Wound healing scratch assay results showed a significant healing rate by 5% and 10% in HFF-1 and HaCaT cells lines, respectively with high cellular migration of fibroblast and keratinocytes. Overall, it can be concluded that the Biofield Energy Healing (The Trivedi Effect®) based test formulation and cell medium could be helpful against various skin disorders and can be used in psoriasis, seborrheic dermatitis, skin cancer, rashes from bacterial or fungal infections as anti-wrinkling, skin-whitening, anti-ageing, and rejuvenating agent.
The study was aimed to evaluate the effect of Consciousness Energy Healing based vitamin D3 and DMEM medium on bone health parameters. The test items, were divided into two parts. One part of each sample received the Consciousness Energy Healing Treatment by Dezi Ann Koster and those samples were labeled as the Biofield Energy Treated (BT) samples, while the other parts of each sample were denoted as the untreated test items (UT). Different parameters were performed for the evaluation of bone health like ALP, collagen, and bone mineralization in human bone osteosarcoma cells (MG-63). The cell viability (MTT) data showed the test samples were found as safe in the tested concentrations. The level of ALP was significantly increased by 431.44% and 436.87% in the BT-DMEM + UT-Test item and BT-DMEM + BT-Test item, respectively at 1 µg/mL compared to the UT-DMEM + UT-Test item group. Further, the ALP level was significantly elevated by 163.34%, 44.91%, and 57.67% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 50 µg/mL compared to the untreated. Collagen was significantly increased by 56.58%, 84.95%, and 43.27% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item, respectively at 0.1 µg/mL compared to the untreated. Further, the collagen level was significantly increased by 21.27%, 47.26%, and 63.1% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 50 µg/mL compared to the untreated. Besides, the percent of bone mineralization was distinctly increased by 41.87% and 91.87% at 1 µg/mL in the BT-DMEM + UT-Test item and BT-DMEM + BT-Test item groups, respectively while, increased by 72.66% and 186.68% at 50 µg/mL in the UT-DMEM + BT-Test item and BT-DMEM + BT-Test item groups, respectively compared to the untreated. The percent of bone mineralization was distinctly increased by 101.21%, 57.76%, and 125.53% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item, respectively at 10 µg/mL compared to the untreated. Altogether, the Biofield Energy Treated vitamin D3 was significantly improved the bone health parameters and it could be an excellent alternative nutraceutical supplement against various bone-related disorders including osteoporosis, low bone density, osteogenesis imperfecta, Paget’s disease, rickets, osteomalacia, deformed bones, autoimmune and inflammatory diseases, stress management and prevention, and anti-aging by improving overall health.
The aim of the present study determined the impact of the Biofield Energy Treated test formulation using cell lines related with vital organs functioning. Different cells based assay were used based on the vital organs function of bones, heart, liver, lungs, and brain. The test formulation and cells media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Dimitrius Anagnos, USA and were labeled as the Biofield Energy Treated (BT) test formulation / media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found non-toxic against all the cell line. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 25.6% (at 63.75 µg/mL), 46.7% (at 0.1 µg/mL), and 109.5% (at 63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 41.3%, 22.8%, and 34.8% at 63.75 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. However, cyto-protective activity in human hepatoma cells (HepG2) showed improved cell viability by 117.7% (at 0.1 µg/mL), 61.3% (at 25.5 µg/mL), and 104% (at 0.1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was significantly increased by 105.7% at 10 µg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 368% and 602% at 0.1 µg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups respectively, as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 58.8% at 1 µg/mL in the UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 32.6% at 25 µg/mL, and improved cellular protection by 60.4% and 109.5% at 25 and 63.75 µg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 35.9% (at 10 µg/mL), 84.2% (at 25.5 µg/mL), and 87.6% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 35.2% (at 0.1 µg/mL), 35.2% (at 0.1 µg/mL), and 79.7% (at 1 µg/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased at 25 µg/mL by 30.6%, 107.7%, and 89.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased at 50 µg/mL by 156.1%, 158.7%, and 68.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, Biofield Energy treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Herbal based test formulations have been used in most of the healthcare settings since time immemorial. The present experimental cell line study was designed to evaluate the impact of the Biofield Energy Treatment on test formulation and different cell line mediums related with vital organs functioning. Cell lines that were specific to different organ systems were used in the study using standard protocols. The Test Item (TI) and specific cell line media (Med) was divided into two parts; one untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Eileen Mary Meagher, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. MTT assay was used for cell viability assay, and the results showed that the test item was found non-toxic. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 56.8% (at 63.75µg/mL), 57.5% (at 63.75µg/mL), and 124.8% (at 1µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group in Human Cardiac Fibroblasts cells (HCF) cells, while 83.2% (at 63.75µg/mL), 93.8% (at 63.75µg/mL), and 20.6% (at 10µg/mL) improved cellular protection of human Hepatoma cells (HepG2) cells in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinoma human alveolar basal epithelial cells (A549) showed improved cell viability by 11.3% (at 25.5µg/mL), 82.7% (at 63.75µg/mL), and 113.9% (at 25.5µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. MG-63 cells were used for estimation of ALP activity, which was highly increased by 59.8% (at 0.1µg/mL), 269.7% (at 0.1µg/mL), and 105.7% (at 0.1µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. Besides, Ishikawa cells showed maximum increased ALP activity by 94.8% at 10µg/mL in the BT-Med+UT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 48.8% (at 1µg/mL), 62.9% (at 10µg/mL), and 103% (at 1µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI group, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. Alanine Amino Transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported at 63.75µg/mL by 74.9% and 84.9% in the BT-Med+UT-TI and BT-Med+BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 21.7% (at 25.5µg/mL), 83.2% (at 0.1µg/mL), and 40% (at 25.5µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 50.8% (at 63.75µg/mL), 35.9% (at 10µg/mL), and 49.9% (at 10µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the Relative Quantification (RQ) of Vitamin D Receptor (VDR) was significantly increased by 135.2%, 291.4%, and 248.3% at 50µg/mL in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Various complementary approaches have been used against multiple organ dysfunction syndrome (MODS), which is the major contributor in high mortality among the healthcare centers. The aim of the present study was to determine the impact of the Biofield Energy Treatment on test formulation and different cell line medium related with vital organs functioning. Different organ based cell lines were used in the study for testing the effects of test formulation. The test item (TI) and specific cell line media (Med) was divided into two parts; one untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Elizabeth Patric, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. MTT assay was used for cell viability assay, and the results showed that the test item was found non-toxic. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 129.7% (at 1 µg/mL), 28.4% (at 63.75 µg/mL), and 44.5% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 53.4% (at 63.75 µg/mL), 14.5% (at 10 µg/mL), and 22.9% (at 25.5 µg/mL) improved cellular protection of human hepatoma cells (HepG2) cells in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinoma human alveolar basal epithelial cells (A549) showed improved cell viability by 25.6% (at 25.5 µg/mL), 59.8% (at 10 µg/mL), and 26.1% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was maximum increased by 84.9% at 50 µg/mL in the BT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 308.1% at 0.1 µg/mL in the BT-Med + BT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 76.7% (at 1 µg/mL), 44.3% (at 1 µg/mL), and 102.6% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported at 63.75 µg/mL by 70.6%, 89.9%, and 76.6% in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 16.2% (at 10 µg/mL), 35.2% (at 63.75 µg/mL), and 17.7% (at 63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 14.6% (at 25 µg/mL), 41.2% (at 1 µg/mL), and 70.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 166.8%, 266.4%, and 153.3% at 0.1 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
The study was aimed to evaluate the effect of Biofield Energy Treated vitamin D3 and DMEM medium on bone health parameters such as ALP, collagen, and bone mineralization in human bone osteosarcoma cells (MG-63). The test items (TI), were divided into two parts. One part of each sample received the Consciousness Energy Healing Treatment by Haddon Norman Salt and those samples were labeled as the Biofield Energy Treated (BT) samples, while the other parts of each sample were denoted as the untreated test items (UT). The cell viability by MTT assay data showed that the test samples were found as safe in the tested concentrations. The level of ALP was significantly increased by 73.24% and 85.41% in the UT-DMEM + BT-Test TI and BT-DMEM + BT-TI, respectively at 10 µg/mL compared to the UT-DMEM + UT-TI group. Further, ALP level was significantly elevated by 76.71% in the BT-DMEM + UT-TI group at 0.1 µg/mL compared to the untreated. Collagen was significantly increased by 77%, 113.53%, and 98.00% in the UT-DMEM + BT-TI, BT-DMEM + UT-TI, and BT-DMEM + BT-TI, respectively at 50 µg/mL compared to the untreated. Further, the collagen level was significantly increased by 128.05% and 132.10% in the UT-DMEM + BT-TI and BT-DMEM + BT-TI groups, respectively at 100 µg/mL; while increased by 76.31% in the BT-DMEM + UT-TI at 10 µg/mL compared to the untreated. Besides, the percent of bone mineralization was distinctly increased by 82.43%, 158.97%, and 52.95% at 0.1 µg/mL in the UT-DMEM + BT-TI, BT-DMEM + UT-TI, and BT-DMEM + BT-TI groups, respectively compared to the untreated. The percent of bone mineralization was significantly increased by 118.41%, 197.42%, and 116.94% in the UT-DMEM + BT-TI, BT-DMEM + UT-TI, and BT-DMEM + BT-TI, respectively at 1 µg/mL compared to the untreated. Further, bone mineralization was significantly increased by 202.34%, 200%, and 235.64% in the UT-DMEM + BT-TI, BT-DMEM + UT-TI, and BT-DMEM + BT-TI, respectively at 10 µg/mL than untreated. Altogether, the Biofield Energy Treated vitamin D3 was significantly improved the bone health parameters and it could be an excellent alternative nutraceutical supplement for vitamin D3 deficiency and fight against various bone-related disorders including osteoporosis, low bone density, osteogenesis imperfecta, Paget’s disease, rickets, osteomalacia, deformed bones, autoimmune and inflammatory diseases, stress management and prevention, and anti-aging by improving overall health.